Title:
ANTI-HUMAN INTERLEUKIN 36 RECEPTOR MONOCLONAL ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/082383
Kind Code:
A1
Abstract:
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementarity determining regions CDR-L1, CDR-L2 and CDR-L3, and the amino acid sequences of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 are as shown in SEQ ID NO: 1 to SEQ ID NO: 6, respectively. Compared with Spesolimab, the monoclonal antibody has comparable binding affinity to human IL-36R, and the neutralizing activity of the monoclonal antibody at the cellular level is superior to that of Spesolimab.
Inventors:
QIU JIWAN (CN)
LI WANG (CN)
ZHOU YI (CN)
CHEN WEI (CN)
KONG YONG (CN)
QIAO HUAIYAO (CN)
WU YILIANG (CN)
CHEN TAO (CN)
LI WANG (CN)
ZHOU YI (CN)
CHEN WEI (CN)
KONG YONG (CN)
QIAO HUAIYAO (CN)
WU YILIANG (CN)
CHEN TAO (CN)
Application Number:
PCT/CN2022/134732
Publication Date:
April 25, 2024
Filing Date:
November 28, 2022
Export Citation:
Assignee:
QYUNS THERAPEUTICS CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P1/00; A61P11/00; A61P13/12; A61P17/00; A61P19/02; A61P29/00; A61P37/02; C12N5/10; C12N15/13; C12P21/08
Attorney, Agent or Firm:
BEIJING TANGSONG IP FIRM (CN)
Download PDF: